Evaluation of the in vitro anticancer activity of cyclometalated half-sandwich rhodium and iridium complexes coordinated to naphthaldimine-based poly(propyleneimine) dendritic scaffolds

Organometallic Iridium Arene Compounds: The Effects ofC-Donor Ligands on Anticancer Activity

“…Complex 26A exhibited high nanomolar potency against chronic myelogenous leukemia, K562 (IC 50 = 0.26¯M), with apoptosis studies showing an induction of apoptosis and an increase in ROS on decreasing MMP (mitochondrial membrane potential). 111 On analysis of the gene expression when K562 cells were treated with this complex, there was an upregulation of Bax and caspase-9 and a downregulation of Bcl-2 and release of cytochrome c, all suggestive of apoptosis through intrinsic mitochondrial apoptosis pathways.…”

Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η5-C5H5)(PPh3)2]+ as Promising Drugs Against Cisplatin-Resistant Cancer Cells and Human Mesenchymal Stem Cells

“…The incorporation of metal complexes in dendritic scaffolds, thus originating metallodendrimers, can increase the activity and selectivity of drugs based on transition metals [ 64 ]. Indeed, metallodendrimers can combine the anticancer potential of metal complexes with the features of the dendrimers as nanocarriers, and were described as having promising cytotoxicity against different cancer cell lines [ 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 ].…”

Organometallic rhodium(iii) and iridium(iii) cyclopentadienyl complexes with curcumin and bisdemethoxycurcumin co-ligands

“…25,26 Recently, more stable cyclopentadienyl Rh(III) and Ir(III) complexes, with higher structural diversity and a higher coordination number (6 versus 4), 27,28 have been shown to have highly potent anticancer activity. [29][30][31][32][33][34][35][36][37][38][39][40] Based on the highly promising pharmacological properties of the arene ruthenium(II) complexes incorporating curcumin and bisdemethoxycurcumin co-ligands, combined with the exciting developments on the anticancer properties of Rh(III) and Ir(III) organometallic compounds, we decided to integrate these two areas and prepare and evaluate some pentamethylcyclopentadienyl Rh(III) and Ir(III) compounds containing curcumin-based ligands and, in some cases, PTA. It should be noted that two curcumin complexes of Rh(III) and Ir(III) have been reported, 41 but structural data and biological studies were not described.…”